| Description |
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1].
|
| Related Catalog |
|
| Target |
CD37[1]
|
| In Vitro |
Otlertuzumab (TRU-016) in combination with Rituximab (HY-P9913), Rapamycin (HY-10219), or Bendamustine (HY-13567) increases cell killing of NHL cells[2]. Otlertuzumab has the ability to bind to and kill CD37+ cells[3].
|
| In Vivo |
Otlertuzumab (TRU-016) in combination with Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice[2]. Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts[3].
|
